 Daix France, August 2, 2021 GLOBE NEWSWIRE Inventiva S.A. NASDAQ: IVA EURONEXT PARIS: IVA the Company, a clinical-stage biotechnological company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the implementation of an At-The-Market ATM program allowing the Company to issue and sell, including with unsolicited investors who have expressed an interest, ordinary shares in the form of American Depositary Shares ADS, each ADS representing one ordinary share of Inventiva, with aggregate gross sales proceeds of up to 100,000,000 subject to a regulatory limit of 20 dilution and within the limits of the investors requests expressed in the context of the program, from time to time, pursuant to the terms of a sale agreement with Jefferies LLC Jefferies, acting as sales agent. The timing of any issuances in the form of ADSs will depend on a variety of factors. The ATM program will be effective until August 2, 2024, unless terminated prior to such date in accordance with the sale agreement or the maximum number of ADSs to be sold thereunder has been reached. 